ES2171439T3 - Composicion a base de aminoacidos para el tratamiento de infecciones. - Google Patents

Composicion a base de aminoacidos para el tratamiento de infecciones.

Info

Publication number
ES2171439T3
ES2171439T3 ES94402420T ES94402420T ES2171439T3 ES 2171439 T3 ES2171439 T3 ES 2171439T3 ES 94402420 T ES94402420 T ES 94402420T ES 94402420 T ES94402420 T ES 94402420T ES 2171439 T3 ES2171439 T3 ES 2171439T3
Authority
ES
Spain
Prior art keywords
cysteine
amino acids
proportion
infections
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94402420T
Other languages
English (en)
Other versions
ES2171439T5 (es
Inventor
Maurice Arnal
Francis Rose
Denis Breuille
Christiane Obled
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Societe des Produits Nestle SA
Nestle SA
Institut National de la Recherche Agronomique
Original Assignee
Societe des Produits Nestle SA
Nestle SA
Institut National de la Recherche Agronomique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9452315&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2171439(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Societe des Produits Nestle SA, Nestle SA, Institut National de la Recherche Agronomique filed Critical Societe des Produits Nestle SA
Application granted granted Critical
Publication of ES2171439T3 publication Critical patent/ES2171439T3/es
Publication of ES2171439T5 publication Critical patent/ES2171439T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

COMPOSICION A BASE DE AMINOACIDOS DESTINADA A SER ADMINISTRADA POR VIA ORAL, ENTERAL O PARENTERAL, CARACTERIZADA POR EL HECHO DE QUE CONTIENE EN UN MEDIO BIOLOGICA Y NUTRICIONALMENTE ACEPTABLE, AL MENOS CISTEINA LIBRE O EN FORMA DE PRECURSOR, PRODROGA, PROTEINA, HIDROLIZADO PEPTIDICO, EN UNA PROPORCION EN CISTEINA FARMACOLOGICAMENTE ACTIVA SUPERIOR A LA PROPORCION DE CISTEINA PRESENTE EN UNA COMPOSICION NUTRICIONAL QUE CORRESPONDE A LAS NECESIDADES DE UN HOMBRE SANO, ESTANDO LA PROPORCION EN CISTEINA DETERMINADA RESPECTO DE LA TOTALIDAD DE LOS AMINOACIDOS PRESENTES EN LA COMPOSICION.
ES94402420T 1993-10-28 1994-10-27 Composicion a base de aminoacidos para el tratamiento de infecciones. Expired - Lifetime ES2171439T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9312884A FR2711529B1 (fr) 1993-10-28 1993-10-28 Composition à base d'acides aminés destinée au traitement d'une infection ou d'une agression engendrant une réaction inflammatoire, chez les animaux et chez l'homme.
FR9312884 1993-10-28

Publications (2)

Publication Number Publication Date
ES2171439T3 true ES2171439T3 (es) 2002-09-16
ES2171439T5 ES2171439T5 (es) 2008-12-01

Family

ID=9452315

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94402420T Expired - Lifetime ES2171439T5 (es) 1993-10-28 1994-10-27 Composicion a base de aminoacidos para el tratamiento de infecciones.

Country Status (9)

Country Link
EP (1) EP0655244B2 (es)
KR (1) KR950010884A (es)
AT (1) ATE216234T1 (es)
CA (1) CA2134380C (es)
DE (1) DE69430416T3 (es)
DK (1) DK0655244T5 (es)
ES (1) ES2171439T5 (es)
FR (1) FR2711529B1 (es)
PT (1) PT655244E (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999038507A1 (en) * 1998-01-30 1999-08-05 David George Le Couteur Reversal and prevention of clinically significant aspects of aging through oral use of hepatic artery vasodilator and other agents which increase hepatic oxygenation
ES2261383T5 (es) * 2000-02-04 2010-06-18 Societe Des Produits Nestle S.A. Un metodo para mantener o mejorar la sintesis de mucinas.
EP1302115A1 (fr) * 2001-10-16 2003-04-16 Societe Des Produits Nestle S.A. Utilisation de cystathionine
US20080032915A1 (en) * 2004-02-12 2008-02-07 Campina Nederland Holding B.V. Cysteine Rich Peptides for Improving Thiol Homeostasis
WO2006134135A2 (en) * 2005-06-14 2006-12-21 Nestec S.A. Nutritional method for elderly people
DE102006018293A1 (de) * 2006-04-20 2007-10-25 Fresenius Kabi Deutschland Gmbh Pädiatrische Aminosäurelösung zur parenteralen Ernäherung
EP2165713B1 (en) 2008-09-19 2012-11-14 Nestec S.A. Whey and thymus function
WO2011021926A1 (en) * 2009-08-21 2011-02-24 N.V. Nutricia Regulating the amino acid pool used for the acute-phase protein synthesis
EP2444083A1 (en) 2010-10-21 2012-04-25 Nestec S.A. Cysteine and food intake
WO2024122796A1 (ko) * 2022-12-05 2024-06-13 의료법인 성광의료재단 아스파르트산을 유효성분으로 포함하는 패혈증의 예방 또는 치료용 약학적 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2531204C2 (de) * 1975-07-12 1987-01-22 Fresenius AG, 6380 Bad Homburg L-Aminosäuregemische für die parenterale oder orale Ernährung
DE2946563C2 (de) * 1979-11-17 1987-04-30 B. Braun Melsungen Ag, 3508 Melsungen Aminosäurelösung zur parenteralen Infusion
DE3026368A1 (de) * 1980-07-11 1982-02-18 Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München Naehrloesung fuer die vollstaendige parenterale ernaehrung und fuer gesteigerte energieproduktion
US4604286A (en) * 1984-09-17 1986-08-05 Daigo Nutritive Chemicals, Ltd. Infusion solution for parenteral nutrition
ES2039402T3 (es) * 1986-10-24 1993-10-01 Pfrimmer Kabi Gmbh & Co. Kg Empleo de peptidos n,n'-bis-l-aminoacido-l-cistina en preparados de aminoacidos para alimentacion oral y parenteral.
SE8704217D0 (sv) * 1987-10-29 1987-10-29 Vinnars Erik Ab Aminosyrakomposition for parenteral neringstillforsel
US5224409A (en) † 1991-03-19 1993-07-06 Ashlock Company Apparatus for producing helical slices
US5214062A (en) † 1992-04-08 1993-05-25 Clintec Nutrition Co. Method and composition for treating immune disorders, inflammation and chronic infections
AU6060694A (en) † 1993-05-10 1994-11-17 Transcend Therapeutics, Inc Method for treating acquired immune deficiency syndrome

Also Published As

Publication number Publication date
ES2171439T5 (es) 2008-12-01
DK0655244T5 (da) 2008-10-13
EP0655244B1 (fr) 2002-04-17
DK0655244T3 (da) 2002-08-05
FR2711529B1 (fr) 1996-07-05
DE69430416T3 (de) 2009-01-22
PT655244E (pt) 2002-08-30
EP0655244B2 (fr) 2008-06-11
KR950010884A (ko) 1995-05-15
DE69430416T2 (de) 2002-12-05
ATE216234T1 (de) 2002-05-15
DE69430416D1 (de) 2002-05-23
EP0655244A1 (fr) 1995-05-31
CA2134380C (en) 2010-06-22
CA2134380A1 (en) 1995-04-29
FR2711529A1 (fr) 1995-05-05

Similar Documents

Publication Publication Date Title
ATE399171T1 (de) Camptothecinanaloge und deren zubereitungsmethoden
TW355683B (en) Composition containing micronized nebivolol
MXPA04005906A (es) Cis-2,4,5-trifenil-.imidazolinas y uso de la misma para tratamiento de tumores.
MXPA02007931A (es) Analogos de nucleosido con base monociclica modificada con carboxamidina.
PE20010284A1 (es) El uso de un antioxidante con ribavirina para preparar un medicamento para el tratamiento de una infeccion viral
MX9701342A (es) Formulacion cosolvente de tirilazad para administracion parenteral.
ATE290015T1 (de) Cyclosporinderivate, deren herstellung und pharmazeutische zubereitungen
CO4790174A1 (es) Analogos del peptido lh-rh, sus usos y composiciones farmaceuticas que los contienen
ATE240344T1 (de) Nor-pregnane zur induzierung hypothalamischer effekte
CO5031291A1 (es) Composicion farmaceutica
ZA901674B (en) Pharmaceutical composition which contains a pharmaceutically suitable carrier and the compound having the structure(7alpha,17alpha)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one
ES2170143T3 (es) Composiciones que comprenden halofantrina en una forma especial.
CO4230093A1 (es) Derivados del indol y sus usos medicos
ES2185153T3 (es) Uso de mefloquina(+) para el tratamiento de la malaria.
PT655244E (pt) Composicao a base de acidos aminados para o tratamento de infeccoes
AR043016A2 (es) Un compuesto antimigranico eletriptan y composicion farmaceutica que lo contiene
IT1250701B (it) Composizione farmaceutica solida per uso orale a base di dapiprazolo
BRPI0415428A (pt) formulações terapêuticas
ATE244010T1 (de) Arzneistoffkombination zur behandlung von kopfschmerzen mit mirtazapine und paracetamol oder nicht-steroiden entzündungshemmenden mitteln
IT1243358B (it) Composizioni farmaceutiche per la somministrazione orale di irudina
ES2053683T3 (es) Forma de medicamento de aplicacion oral para el tratamiento de la hipertension una vez al dia con hidrocloruro de diltiazem.
ATE426631T1 (de) 1-vinylpyrrolidin-2-on/ester copolymere
AR038847A1 (es) Uso del compuesto n-(3,5-dicloro-2-metoxi-fenil) -4-metoxi-3-piperazin-1-il-bencenosulfonamida para la elaboracion de una composicion farmaceutica y dicha composicion farmaceutica
DE60040856D1 (de) Lactalbumin zur kurativen Behandlung von Magengeschwüren
ECSP045295A (es) Composiciones farmacéuticas que comprenden 2-(4-etoxi-fenil)-3-(4-metanosulfonil-fenil)-pirazolo'1,5-bipiridacina en forma nanoparticulada

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 655244

Country of ref document: ES